During the corresponding time, Palatin Technologies Inc sequentially revenue grew by 3278.84 %. While revenue at the Palatin Technologies Inc 's corporate clients
Palatin Technologies Inc's Comment on Sales, Marketing and Customers
The company focuses on markets related to obesity, metabolic disorders, rare MC4R pathway diseases such as hypothalamic obesity, orphan indications, and erectile dysfunction. Its target patient segments include individuals with obesity and diabetes, particularly those treated with GLP-1 receptor agonists like Wegovy and Ozempic (semaglutide). The company also addresses chronic weight management in adult and pediatric patients aged six years and older with monogenic or syndromic obesity, as indicated by the use of melanocortin agonists such as Imcivree® (setmelanotide) marketed by Rhythm Pharmaceuticals. In the area of erectile dysfunction, the company focuses on patients who do not respond adequately to PDE5 inhibitor monotherapy; commonly used PDE5 inhibitors include sildenafil (Viagra®), tadalafil (Cialis®), vardenafil (Levitra®), and avanafil (Stendra®). The company operates in a competitive environment alongside pharmaceutical firms such as Novo Nordisk, Sanofi, Merck, Eli Lilly, Roche, Pfizer, Regeneron, and Altimmune.
Palatin Technologies Inc’s Comment on Sales, Marketing and Customers
The company focuses on markets related to obesity, metabolic disorders, rare MC4R pathway diseases such as hypothalamic obesity, orphan indications, and erectile dysfunction. Its target patient segments include individuals with obesity and diabetes, particularly those treated with GLP-1 receptor agonists like Wegovy and Ozempic (semaglutide). The company also addresses chronic weight management in adult and pediatric patients aged six years and older with monogenic or syndromic obesity, as indicated by the use of melanocortin agonists such as Imcivree® (setmelanotide) marketed by Rhythm Pharmaceuticals. In the area of erectile dysfunction, the company focuses on patients who do not respond adequately to PDE5 inhibitor monotherapy; commonly used PDE5 inhibitors include sildenafil (Viagra®), tadalafil (Cialis®), vardenafil (Levitra®), and avanafil (Stendra®). The company operates in a competitive environment alongside pharmaceutical firms such as Novo Nordisk, Sanofi, Merck, Eli Lilly, Roche, Pfizer, Regeneron, and Altimmune.
Sources:
Palatin Technologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Palatin Technologies Inc’s corporate clients.
For your research, we’ve provided 9 tables on Palatin Technologies Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
